Literature DB >> 8890659

Cryptosporidiosis among patients infected with human immunodeficiency virus. Factors related to symptomatic infection and survival.

J M Colford1, I B Tager, A M Hirozawa, G F Lemp, T Aragon, C Petersen.   

Abstract

The authors reviewed the medical records of 194 human immunodeficiency virus (HIV)-positive patients newly diagnosed with cryptosporidiosis and all 3,564 patients with newly diagnosed acquired immunodeficiency syndrome (AIDS) at San Francisco General Hospital for the period 1986-1992. The study was designed to address three questions: 1) How do AIDS patients who present with cryptosporidiosis differ from other patients with AIDS? 2) What factors are associated with survival among AIDS patients with newly diagnosed cryptosporidiosis? 3) Does a diagnosis of cryptosporidiosis impact survival after AIDS diagnosis? A total of 194 cases of cryptosporidiosis among HIV-infected patients were identified during the study period. Of the 194 patients, 109 (56%) had no prior diagnosis of AIDS. These 109 patients represented 3.1% of the 3,564 newly diagnosed cases of AIDS in the same period. Among the 134 patients with CD4 T-lymphocyte counts performed within 3 months of Cryptosporidium diagnosis, 34 (25%) had CD4 counts greater than 209 cells/ml. In a multivariate conditional logistic regression model, the incidence of Cryptosporidium was related to ethnicity (for blacks vs. whites, matched odds ratio (OR) = 0.15, 95% confidence interval (CI) 0.03-0.73), CD4 count (for a CD4 count of < or = 53 cells/ml vs. > 53 cells/ml, matched OR = 12.60, 95% CI 4.01-39.61), and age (for a 10-year increase, matched OR = 0.51, 95% CI 0.27-0.98). Two factors measured at the time of Cryptosporidium diagnosis were identified as being independently associated with survival (p < 0.001) in the proportional hazards model: CD4 count < or = 53 cells/ml versus > 53 cells/ml (relative hazard = 6.18, 95% CI 2.99-12.76) and hematocrit < or 37% versus > 37% (relative hazard = 2.27, 95% CI 1.22-4.22). The median durations of survival in the four subgroups of Cryptosporidium-infected patients defined by these two variables differed significantly from each other (range, 204-1,119 days). Cryptosporidiosis as an initial AIDS-defining diagnosis was associated with an elevated relative hazard of death in comparison with other AIDS-defining diagnoses (relative hazard = 2.01, 95% CI 1.38-2.93). These data identify the groups of HIV-infected individuals at risk for presentation with symptomatic Cryptosporidium infection; the distinct survival patterns among subgroups of those patients already infected with this parasite; and the survival of AIDS patients with newly diagnosed cryptosporidiosis relative to patients with other AIDS-defining conditions. Such information is necessary for the design of prospective studies, the development of prophylactic strategies, the evaluation of candidate therapies, and the provision of prognostic information to patients.

Entities:  

Mesh:

Year:  1996        PMID: 8890659     DOI: 10.1093/oxfordjournals.aje.a009015

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  35 in total

1.  Evaluation of ColorPAC Giardia/Cryptosporidium rapid assay and ProSpecT Giardia/Cryptosporidium microplate assay for detection of Giardia and Cryptosporidium in fecal specimens.

Authors:  M T Katanik; S K Schneider; J E Rosenblatt; G S Hall; G W Procop
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Human intestinal and biliary cryptosporidiosis.

Authors:  Xian-Ming Chen; Nicholas F LaRusso
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

3.  Occurrence of Cryptosporidium oocysts in sewage effluents and correlation with microbial, chemical and physical water variables.

Authors:  Lucia Bonadonna; Rossella Briancesco; Massimo Ottaviani; Enrico Veschetti
Journal:  Environ Monit Assess       Date:  2002-05       Impact factor: 2.513

4.  Opportunistic intestinal infections and risk of colorectal cancer among people with AIDS.

Authors:  Fatma M Shebl; Eric A Engels; James J Goedert
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-02       Impact factor: 2.205

5.  CpABC, a Cryptosporidium parvum ATP-binding cassette protein at the host-parasite boundary in intracellular stages.

Authors:  M E Perkins; Y A Riojas; T W Wu; S M Le Blancq
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

6.  Molecular characterization of Cryptosporidium spp. from children in Kolkata, India.

Authors:  Pradeep Das; Seuli Saha Roy; Kakali MitraDhar; Phalguni Dutta; Mihir K Bhattacharya; Abhik Sen; Sandipan Ganguly; Sujit K Bhattacharya; Altaf A Lal; Lihua Xiao
Journal:  J Clin Microbiol       Date:  2006-09-13       Impact factor: 5.948

Review 7.  Infections by Intestinal Coccidia and Giardia duodenalis.

Authors:  Vitaliano A Cama; Blaine A Mathison
Journal:  Clin Lab Med       Date:  2015-04-04       Impact factor: 1.935

8.  Biphasic modulation of apoptotic pathways in Cryptosporidium parvum-infected human intestinal epithelial cells.

Authors:  Jin Liu; Mingqi Deng; Cheryl A Lancto; Mitchell S Abrahamsen; Mark S Rutherford; Shinichiro Enomoto
Journal:  Infect Immun       Date:  2008-12-15       Impact factor: 3.441

9.  Evaluation of a screening test for detection of giardia and cryptosporidium parasites.

Authors:  Sojin Youn; Mamun Kabir; Rashidul Haque; William A Petri
Journal:  J Clin Microbiol       Date:  2008-12-03       Impact factor: 5.948

10.  The Serologic response to Cryptosporidium in HIV-infected persons: implications for epidemiologic research.

Authors:  J N Eisenberg; J W Priest; P J Lammie; J M Colford
Journal:  Emerg Infect Dis       Date:  2001 Nov-Dec       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.